In a colon cancer model induced by AOM (azoxymethane)/DSS (dextran sulfate sodium), the KDM6A/B-specific inhibitor GSK-J4 markedly reduced the number of tumors (13 per mouse) compared to the inactive GSK.J2 (22 per mouse). This evidence concerns the gene KDM6A and colonic neoplasm.